This presentation is intended to facilitate continuing medical education.

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views of Sanofi.

Sanofi does not recommend the use of its products in any manner inconsistent with that described in the local package insert.

Before using any product mentioned here-in please refer to the full local prescribing information.

Mucopolysaccharidosis II: A South African Case Study

DR GJM WOLMARANS 28 FEBRUARY 2015

Patient T.R.

- ▶ 4 years 3 months old boy
- Only child
- ► Known to me since 2011
- ► Family history:
 - ► Father Burkitt lymphoma
- Past medical history:
 - ► 2011: Admission # Gastroenteritis
 - ► 2011: Admission # Severe upper respiratory tract infection with vomiting
 - ▶ 2011: # Mitral valve regurgitation secondary to mitral valve prolapse
 - 2013: Admission # Bronchopneumonia
 - 2013: # Mucopolysaccharidosis II (Hunter syndrome) enzyme studies, confirmed with 2 subsequent PCR tests

Medication

- ► Started in October 2014
- Portocath 1st week of December 2014
- ► Allergic reaction on 14 January 2015

Signs and symptoms

- ► Growth:
 - ► Currently on 50th centile
- Performance:
 - ► Hyperactive
- Craniofacial:
 - Coarsening of facial features
 - ► Full lips
 - Macrocephaly

- Joints and skeletal:
 - ► Stiff partial contracture of joins
 - Claw hand
 - ► Short neck
- Neurological / Development:
 - ► Speech delay
- Other:
 - ► PSM over apex
 - Umbilical hernia




Figure 2 - MPS patient: Type II (5y).

Diagnosis: Screening

Parameter	Result	Reference	range	
Lysosomal Enzymes from D	ried Blood			
alpha-Iduronidase (MSMS)	1198.87	350 - 2614	pmol/spot*20h	
iduronate-2-sulfatase	0	- 0,02 - 0,25	nmol/spot*21h	
Arylsulfatase B	0.26	0,14 - 0,7	nmol/spot*21h	
beta-galactosidase	0.69	0,5 - 3,2	nmol/spot*21h	

Evaluation

Dear colleague,

the activity of iduronate-2-sulfatase is below its reference range. This may be in agreement with an MPS II and confirms the previous findings. We recommend a molecular genetic assay for final confirmation. The other enzyme activities above are within their respective reference ranges. Thus, there is no indication of MPS I and MPS VI.

If you have any questions feel free to contact us anytime.

Diagnosis: Confirmation

Indication:	MPS II	Sample material: Dried blood spot
Methods:	DNA extraction, PCR and sequencing of exons 1, 2, Official symbol: IDS Gene ID: 3423 Reference sequence: ENST00000340855 (ENST00	
Result:	The following mutation was detected: c.[1509G>A] (p.[Trp502*])	
Interpretation:	The c.1509G>A results in a nonsense mutation (prepatient.	emature stop) and confirms MPS II in your

MPS II in South Africa: Reality?

- Patient
- Parents
- Diagnosis
- Treatment
- Medicine Control Council
- Medical Aids
- ► Follow-up
- Relationship between Pharmaceutical companies and clinicians

Patient

- Early onset of signs
- Difficult diagnosis
- Rare condition
- Complications or co-existing conditions
- ► Side effects of treatment
- Prevention of progression
- Death before 15 years

Parents

- Denial
- Counselling
- Parent discussions
- ► Lifestyle changes
- Impact on employment

Support structure

Diagnosis

- ► Expense
- Acceptance of diagnosis
- Delay between diagnosis and start of treatment

Treatment

► Idursulfase 0.5 mg/kg per week

- Weekly infusion
- Permanent port for infusion
- Bone marrow transplant
- Risk of anaphylaxis
- International Guidelines helpful
- Expensive

Medicine Control Council

- ► Forms (16 pages)
- Reapply every 6 months
- Progress report every 6 months
- ► Fee with every application
- Quick response



3	- 42	M	44
AND.		7	
	(E		-
		20	

health

Department: Health REPUBLIC OF SOUTH AFRICA

MEDICINES CONTROL COUNCIL The Registrar of Medicines, Private Bag X828, PRETORIA, 0001

Tel: Fax:

FAX AND MAIL

TO:

Enquines: Reference:

MISS	BOITUMELO MAHLANGU	
------	--------------------	--

ELAPRASE

Please include this letter with any future correspondence to our offices to facilitate efficient

05/07/2015 23 February 2015

			05/07/2015		
Dr GJM Wolmarans		Datum * Date	23 February 2015		
PO	sia Medical Centr Box 14739 wille	re		Tel: Fax:	0123958196 0862743073
0129					
Fax	0125490953				
-	r Dr Wolmarans, QUEST TO USE U	INREGISTERED MEDICINE IN TERMS OF IROL ACT, 1965 (ACT 101 OF 1965):			
	r application	13 Feb 2015 refers	fistur	e correst	e this letter with condence to ou
A. B.	STATUS:	Approved. Dr GJM Wolmarans	proce	es to faci essing of mentatio	

IMPORTING COMPANY: Sanofi-aventis South Africa (Pty) Ltd C.

PATIENT/(S): D.

UNREGISTERED MEDICINES: E. idursulfase GENERIC NAME: TRADE NAME: 10-18 vials per month x 6 months QUANTITY: 05/07/2015 N2/19/9/1 APPROVAL NUMBER:

F. We acknowledge receipt as proof of payment.

Both the supplier and the Medicines Control Council should receive a full Progress Report at the time of termination of treatment (31 July 2015). In the case of long term treatment a follow-up report must be submitted every six months. A new authorisation number must be obtained every six months

Yours faithfully,

Pro -

Dr S Munbodh for and on behalf of REGISTRAR OF MEDICINES MCC SECTION 21 REFERENCE NO: \$150213/30

Medical Aids

- ► Applications for:
 - ► Chronic medicine
 - Prescribed Minimum Benefits (PMB)

- Approval takes a long time
- Contact person
- Involvement of the Rare Diseases Society

Follow-up

- Medication
- Pathology
- ► Radiology
- Other specialities and associated health services

Follow-up: Medication

- ► Weekly infusions = 52 per year
- Requirements:
 - ► 2 vials of Idursulfase
 - ▶ 0.9% Saline 100 ml
 - Jelco Catheter
 - Syringes and Needles
 - Infusion set
- Apply for everything separately as part of PMB
- Home infusions / Infusion Centres / In-hospital

Follow-up

Pathology

Urinary GAGs – twice a year

Radiology

- Abdominal ultrasound twice a year
- X-ray: Pelvis, lateral spine and neck twice a year
- ► Echocardiogram twice a year
- MRI Craniocervical junction (if radiological changes on X-ray) – once a year

Follow-up: Other specialities and associated health services

- Paediatrician twice a year
- Paediatric Neurologist twice a year
- Paediatric Pulmonologist twice a year
- Ophthalmologist twice a year
- Paediatric Cardiologist twice a year
- Apnoea / Hypopnoea index once a year
- Sleep study once a year
- Audiology once a year

Relationship between Pharmaceutical Companies and clinicians

- Information regarding these rare diseases
- Measurements
- Section 21 applications
- Screening and confirmation testing
- Support
- Contact with Medical Aids

Thank you!